Drug
Amprenavir clinical trials
- studies test it
- 21
- open now
- 0
- in phase 3
- 3
- first study started
- 1997
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 1999 (5)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1999 | 5 |
| 2000 | 2 |
| 2001 | 3 |
| 2003 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 12
- Phase 3
- 3
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 8
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Glaxo Wellcome (7) · Boehringer Ingelheim (2) · Abbott (2) · ANRS, Emerging Infectious Diseases (1) · Hoffmann-La Roche (1) · Gilead Sciences (1)
Often tested with
Tested in the same studies.
Abacavir (11) · Ritonavir (7) · Efavirenz (6) · Saquinavir (3) · Lamivudine (3) · Adefovir dipivoxil (2) · Indinavir (2) · Tipranavir (1)
Studies
Open first, then newest update. How each study uses amprenavir is read from its arms, and is right about nine times in ten.
Testing it · 21
- Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT00196625Written as Amprenavir (drug)
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedPhase 2Boehringer IngelheimNCT00056641Written as amprenavir
- A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken AmprenavirCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001095Written as Amprenavir
- Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00005762Written as Amprenavir
- Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIVCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000940Written as Amprenavir
- A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive PatientsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000912Written as Amprenavir
- Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00006617Written as Amprenavir
- Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive AdultsTerminatedPhase 1Boehringer IngelheimNCT02182765Written as Amprenavir
- Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAARTCompletedPhase 2AbbottNCT00038532Written as Amprenavir/ritonavir
- Continued Antiretroviral Therapy With Abacavir, Amprenavir and EfavirenzCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001758Written as Amprenavir
- Once-Daily Drug Regimen for HIV-Infected PatientsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001968Written as Amprenavir
- Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease InhibitorCompletedPhase 2/3AbbottNCT00038519Written as Amprenavir/ritonavir
- A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected AdultsCompletedPhase 2Hoffmann-La RocheNCT00002239Written as Amprenavir
- A Study of Amprenavir in Patients With Protease Inhibitor-Related ComplicationsCompletedNot applicableGlaxo WellcomeNCT00002417Written as Amprenavir
- Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor TreatmentCompletedPhase 2Gilead SciencesNCT00002419Written as Amprenavir
- A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirCompletedPhase 2Glaxo WellcomeNCT00002423Written as Amprenavir
- A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected PatientsCompletedPhase 3Glaxo WellcomeNCT00002245Written as Amprenavir
- Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease InhibitorsCompletedPhase 3Glaxo WellcomeNCT00002193Written as Amprenavir
- A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionCompletedPhase 2Glaxo WellcomeNCT00002233Written as Amprenavir
- A Study of Amprenavir in HIV-Infected PatientsCompletedNot applicableGlaxo WellcomeNCT00002405Written as Amprenavir
Codes
What other systems call amprenavir · ClinicalTrials.gg INT003865
- MeSH (NLM) C095108amprenavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5S0W860XNRAMPRENAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 228656Confirmed FDA, Wikidata
- Wikidata Q422198amprenavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28824AmprenavirOne source FDA
- DrugBank DB00701One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C095108 | amprenavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5S0W860XNR | AMPRENAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 228656 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422198 | amprenavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28824 | Amprenavir | One source FDA |
| DrugBank | DB00701 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.